KR20180085068A - 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 - Google Patents
무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 Download PDFInfo
- Publication number
- KR20180085068A KR20180085068A KR1020187020728A KR20187020728A KR20180085068A KR 20180085068 A KR20180085068 A KR 20180085068A KR 1020187020728 A KR1020187020728 A KR 1020187020728A KR 20187020728 A KR20187020728 A KR 20187020728A KR 20180085068 A KR20180085068 A KR 20180085068A
- Authority
- KR
- South Korea
- Prior art keywords
- compounds
- agonist activity
- beta2 adrenergic
- receptor antagonist
- receptor agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169535.9 | 2011-06-10 | ||
| EP11169535 | 2011-06-10 | ||
| PCT/EP2012/060782 WO2012168349A1 (en) | 2011-06-10 | 2012-06-07 | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137032137A Division KR101906630B1 (ko) | 2011-06-10 | 2012-06-07 | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20180085068A true KR20180085068A (ko) | 2018-07-25 |
Family
ID=46458445
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137032137A KR101906630B1 (ko) | 2011-06-10 | 2012-06-07 | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
| KR1020187020728A KR20180085068A (ko) | 2011-06-10 | 2012-06-07 | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137032137A KR101906630B1 (ko) | 2011-06-10 | 2012-06-07 | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9012644B2 (ko) |
| EP (1) | EP2718281B1 (ko) |
| KR (2) | KR101906630B1 (ko) |
| CN (1) | CN103547575B (ko) |
| AR (1) | AR086896A1 (ko) |
| BR (1) | BR112013030302B1 (ko) |
| CA (1) | CA2838777C (ko) |
| RU (1) | RU2606121C2 (ko) |
| TW (1) | TWI545121B (ko) |
| WO (1) | WO2012168349A1 (ko) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| CA2893627C (en) | 2012-12-06 | 2021-09-14 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| GEP20186839B (en) | 2012-12-06 | 2018-04-10 | Chiesi Farma Spa | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| ES2750523T3 (es) | 2012-12-18 | 2020-03-26 | Almirall Sa | Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AR104828A1 (es) | 2015-06-01 | 2017-08-16 | Chiesi Farm Spa | COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO |
| CN107074833B (zh) * | 2015-07-21 | 2021-05-25 | 四川海思科制药有限公司 | 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途 |
| EP3383867B1 (en) | 2015-12-03 | 2021-04-14 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| WO2018011090A1 (en) | 2016-07-13 | 2018-01-18 | Chiesi Farmaceutici S.P.A. | Hydroxyquinolinone compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| CA3047212A1 (en) * | 2017-01-30 | 2018-08-02 | Chiesi Farmaceutici S.P.A. | Tyrosine amide derivatives as rho- kinase inhibitors |
| TW201835041A (zh) * | 2017-02-17 | 2018-10-01 | 印度商托仁特生技有限公司 | 具β-腎上腺素促效劑及抗蕈毒活性化合物 |
| TW202019923A (zh) * | 2018-07-16 | 2020-06-01 | 義大利商吉斯藥品公司 | 作為Ｒｈｏ－激酶抑制劑之酪胺酸醯胺衍生物 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US6417367B1 (en) | 2000-08-11 | 2002-07-09 | Pfizer Inc. | Methods of making quinoline amides |
| TW200303304A (en) * | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| US7060712B2 (en) | 2003-05-08 | 2006-06-13 | Theravance, Inc. | Crystalline form of aryl aniline β2 adrenergic receptor agonist |
| US7358244B2 (en) * | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
| ES2329586T3 (es) | 2003-11-21 | 2009-11-27 | Theravance, Inc. | Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino. |
| ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| JP2008510015A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| EP1778626A1 (en) | 2004-08-16 | 2007-05-02 | Theravance, Inc. | Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| CA2679059A1 (en) | 2007-02-28 | 2008-09-04 | Cipla Limited | Process for preparing isomers of carmoterol |
| EP2080523A1 (en) | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Compositions comprising an antimuscarinic and a long-acting beta-agonist |
| SI2421849T1 (sl) | 2009-04-23 | 2013-07-31 | Theravance, Inc. | Diamidne spojine, ki imajo za muskarinske receptorje antagonistično in za beta 2 adrenergične receptorje agonistično aktivnost |
| WO2011048409A1 (en) | 2009-10-20 | 2011-04-28 | Astrazeneca Ab | Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| CN103562198B (zh) | 2011-06-10 | 2016-08-24 | 奇斯药制品公司 | 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物 |
-
2012
- 2012-06-07 CA CA2838777A patent/CA2838777C/en not_active Expired - Fee Related
- 2012-06-07 BR BR112013030302-6A patent/BR112013030302B1/pt not_active IP Right Cessation
- 2012-06-07 EP EP12732561.1A patent/EP2718281B1/en active Active
- 2012-06-07 WO PCT/EP2012/060782 patent/WO2012168349A1/en active Application Filing
- 2012-06-07 RU RU2013154590A patent/RU2606121C2/ru active
- 2012-06-07 KR KR1020137032137A patent/KR101906630B1/ko active IP Right Grant
- 2012-06-07 KR KR1020187020728A patent/KR20180085068A/ko not_active Application Discontinuation
- 2012-06-07 CN CN201280024634.XA patent/CN103547575B/zh not_active Expired - Fee Related
- 2012-06-08 AR ARP120102063A patent/AR086896A1/es not_active Application Discontinuation
- 2012-06-08 US US13/492,188 patent/US9012644B2/en not_active Expired - Fee Related
- 2012-06-08 TW TW101120663A patent/TWI545121B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| TWI545121B (zh) | 2016-08-11 |
| CN103547575B (zh) | 2016-08-17 |
| US20130034504A1 (en) | 2013-02-07 |
| AR086896A1 (es) | 2014-01-29 |
| TW201302728A (zh) | 2013-01-16 |
| CN103547575A (zh) | 2014-01-29 |
| RU2013154590A (ru) | 2015-06-20 |
| BR112013030302A2 (pt) | 2017-06-27 |
| EP2718281B1 (en) | 2015-09-09 |
| KR20140028055A (ko) | 2014-03-07 |
| CA2838777C (en) | 2019-04-30 |
| CA2838777A1 (en) | 2012-12-13 |
| WO2012168349A1 (en) | 2012-12-13 |
| BR112013030302B1 (pt) | 2021-08-24 |
| RU2606121C2 (ru) | 2017-01-10 |
| KR101906630B1 (ko) | 2018-10-10 |
| EP2718281A1 (en) | 2014-04-16 |
| US9012644B2 (en) | 2015-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180915T1 (hr) | Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora | |
| KR20180085068A (ko) | 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물 | |
| ZA201309242B (en) | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| PL2928890T3 (pl) | Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych | |
| IL215554A0 (en) | Diamide compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity | |
| RS55047B1 (sr) | Novi cikloheksilaminski derivati koji imaju aktivnosti beta2 adrenergijskog agonista i m3 muskarinskog antagonista | |
| EP2927224B8 (en) | Receptor antagonists | |
| LT2569308T (lt) | Naujieji cikloheksilamino dariniai, turintys beta2 adrenerginio agonisto ir m3 muskarininio antagonisto aktyvumus | |
| HK1197240A1 (en) | New cyclohexylamine derivatives having beta 2 adrenergic agonist and m3 muscarinic antagonist activities 2 m3 | |
| IL239118A0 (en) | New cyclohexyl and quinoclidinyl carbamate compounds with beta-2 adrenergic agonistic and m3 muscarinic antagonistic activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |